Company Description
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples.
The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.
This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services.
The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products.
It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies.
Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Nov 20, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 570 |
| CEO | William Martin |
Contact Details
Address: 10770 Wateridge Circle, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 546 0004 |
| Website | maravai.com |
Stock Details
| Ticker Symbol | MRVI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $27.00 |
| CIK Code | 0001823239 |
| CUSIP Number | 56600D107 |
| ISIN Number | US56600D1072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William E. Martin III | Chief Executive Officer and Director |
| Dr. Peter Michael Leddy Ph.D. | Executive Vice President and Chief Administrative Officer |
| Christine Dolan | Executive Vice President and GM of Cygnus Technologies |
| Robert Andrew Eckert MBA | Chairman of the Board |
| Debra Hart | Senior Director of Investor Relations |
| Kurt Oreshack J.D. | Executive Vice President, General Counsel and Secretary |
| Rebecca Buzzeo | Executive Vice President and Chief Commercial Officer |
| Dr. Kate E. Broderick Ph.D. | Executive Vice President and Chief Innovation Officer |
| Christopher C. Benoit | Executive Vice President and Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 4, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 20, 2025 | UPLOAD | Filing |
| Jan 31, 2025 | 144 | Filing |
| Jan 28, 2025 | SCHEDULE 13G/A | Filing |
| Jan 8, 2025 | 8-K | Current Report |
| Dec 18, 2024 | 8-K | Current Report |